SPRUCE BIOSCIENCES, INC. (SPRB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US85209E2081
SPRUCE BIOSCIENCES, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -36.51 m USD |
| EBIT | -38.88 m USD |
| Net income | -38.97 m USD |
| Diluted EPS – continuing operations | -50.83 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SPRUCE BIOSCIENCES, INC.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
More stocks
- UNITED BANCSHARES INC/OH (UBOH)
- Moller Y Perez (MOLLER.SN)
- Namyang Dairy Products Co Ltd Peffered Series 1 (003925.KS)
- e-Credible Co. Ltd (092130.KQ)
- Jw Life Science Corp (234080.KS)
- EI Power Berhad (0453.KL)
- EASY BIOInc (353810.KQ)
- Excelliance MOS (5299.TWO)
- Helixmith Co. Ltd (084990.KQ)
- Foghorn Therapeutics Inc. (FHTX)
- Lucara Diamond Corp (LUC.TO)
- MAXCYTE, INC. (MXCT)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.